Developing Strong Partnerships to Ensure Success With Global Medical Device Trials. 23-February-2017, OCT Burlingame

Size: px
Start display at page:

Download "Developing Strong Partnerships to Ensure Success With Global Medical Device Trials. 23-February-2017, OCT Burlingame"

Transcription

1 Developing Strong Partnerships to Ensure Success With Global Medical Device Trials 23-February-2017, OCT Burlingame With you, for you

2

3 Agenda Identify the core group of stakeholders who will evolve throughout the course of the trial Ensure that the infrastructure is adapted to deliver on the ambition of a global study Understand the landscape of a global medical device trial within the different regions Continuously measure of project progress and instigate pro-active adaptability based on experience and data analytics

4 Identify The Core Group of Stakeholders Who Will Evolve Throughout The Course Of The Trial Effective and open communication from the study start up Set up of frequent team meetings to discuss study progress. Define clear and realistic expectations from all stakeholders. Communicate any changes to the study plan that can affect study outcome.

5 Identify The Core Group of Stakeholders Who Will Evolve Throughout The Course Of The Trial The Sponsor or CRO identifies the team leaders involved in the study. Define and delegate the responsibilities of each of the stakeholders and the steps for escalating study related issues. Understand that the core group of stakeholders will evolve throughout the trial but through effective communication the impact on the trial can be quickly addressed.

6 Identify The Core Group of Stakeholders Who Will Evolve Throughout The Course Of The Trial Sponsor CRO Clinical Research Sites Project Management Monitoring Safety EDC Regulatory Stakeholders: Who s views and decisions will affect the outcome of the trial.

7 Identify The Core Group of Stakeholders Who Will Evolve Throughout The Course Of The Trial Pro-activeness Core Group of Stakeholders Effective Communication Delegation of Responsibilities

8 Understand the Landscape of a Global Medical Device Trial Within the Different Regions Regulators USA: FDA regulations (21CRF, FDA guidance) Europe EU - ISO clinical investigations of medical devices in human subjects (Council) Directives MEDDEV guidelines National requirements Worldwide: ICH-GCP: ICH topic E6 Guideline for good clinical practice, version published 2002

9 Understand the Landscape of a Global Medical Device Trial Within the Different Regions Clinical Research Sites Development of site selection qualifications Selection of sites sponsor has working relationships with Recommendation of sites that CROs have experience working with Contract negotiation timelines IRB/EC Approval timelines Addressing language barriers and cultural differences Site Selection Contract Negotiations IRB/EC Approval Site Initiation Enrollment

10 Understand the Landscape of a Global Medical Device Trial Within the Different Regions Time zones Global trials require proper oversight for the different time zones. Ensuring adequate coverage and availability of the team leaders for the different phases of the trial (from contract negotiation through study closure). Coordinating team meetings within the different time zones to ensure effective communication of study progress and or issue resolution. Considering time zones for site initiation and enrollment (during summer time enrollment might be slower due to vacations; summer time varies depending on the time zone of that region).

11 Ensure That The Infrastructure Is Adapted To Deliver On The Ambition Of a Global Study Communication plan Objectives To effectively provide study updates and study progress. To define appropriate escalation of issue resolution Stakeholders Define each of their roles in communication during the trial Describe way of communication (ex. Via , fax) Global Ensure that the communication plan covers the different regions Communication plan will change as the trial progresses

12 Ensure That The Infrastructure Is Adapted To Deliver On The Ambition Of a Global Study Quality Management System Should effectively manage all of the documents, and activities that must be administered and controlled throughout the life of a clinical trial. Facilitates crossfunctional activities through the trial. It is a framework for defining and delivering quality outcomes, managing risk and continuous improvement on a global level.

13 Ensure That The Infrastructure Is Adapted To Deliver On The Ambition Of a Global Study Project plan Objectives Timelines Resources Associated Risks What is the desired outcome of the trial? Define projected study startup timeframe Deadline for IRB reviews and approvals Study team and delegated responsibilities EDC systems to be used Define the risk associated with conducting the protocol. Mitigation plan for any problems that arise.

14 Ensure That The Infrastructure Is Adapted To Deliver On The Ambition Of a Global Study Budget Regular review of study budget with project management team is key to ensure that the project is staying on budget, and to address any issues that could affect the study budget. Clinical Development Data Management Biostatistical Regulatory Clinical Study Site Subject Reimbursement

15 Continuously Measure Of Project Progress And Instigate Pro- Active Adaptability Based On Experience & Data Analytics Continuous Review of Key Performance Indicators (KPI) Dashboard Sep'16 Oct'16 Nov'16 Dec'16 Patient Enrolled Subjects in EDC Total SDV

16 Continuously Measure Of Project Progress And Instigate Pro- Active Adaptability Based On Experience & Data Analytics Strategic Data Review and Discussion of Action Plans Will provide accurate measure of project progress allowing the project team to: Address early on enrollment issues that can be addressed either by additional follow-up with study sites, or review enrollment criteria on the study protocol. Evaluate low enrolling or poor performing sites to determine if they can continue in the study. Focus of monitoring activities based on the study data available. Continuous review and discussion with management team of study progress and escalate as appropriate to pro-actively address any issues.

17 US experience With experience of studies involving 200+ US sites, genae has the expertise you need to conduct trials of all sizes and complexity worldwide.

18 genae can support your global and local project. With you, for you. genae Americas Inc Cleveland, OH genae associates Antwerp, Belgium genae International AG Zürich, Switzerland genae Japan GK Tokyo, Japan genae NY New York, NY genae SF San Francisco, CA genae UK Ltd London, UK genae Germany GmbH Frankfurt, Germany genae Poland Warsaw, Poland genae Gulf FZ LLC Dubai, UAE genae CoreMed - Strategic Alliance Beijing, China

19 Q&A

20 Accelerating innovation through collaborative insights & global expertise with results that matter Dedicated to Medical Devices, delivering what is promised With you, for you

Meeting sponsor s criteria : strategy to collaborate, engage and deliver

Meeting sponsor s criteria : strategy to collaborate, engage and deliver Meeting sponsor s criteria : strategy to collaborate, engage and deliver Frédérique Couttet Clinical Trial Manager 4th Annual Outsourcing in Clinical Trials Europe Brussels, Switzerland, May 21 22, 2014

More information

MCRA Clinical More Than Your Average CRO. Clinical Project Management. Site Management and Study Monitoring. Data Management. Auxiliary Services

MCRA Clinical More Than Your Average CRO. Clinical Project Management. Site Management and Study Monitoring. Data Management. Auxiliary Services MCRA s unique Clinical Research Organization (CRO) enables international and US-based orthopedic companies of all sizes to successfully execute a clinical study. Our philosophy is to streamline the clinical

More information

OCTC 2012 CRO Selection

OCTC 2012 CRO Selection OCTC 2012 CRO Selection Colin Macaulay Viron Therapeutics Inc. 15 Nov 2012 Viron Therapeutics Inc. Virtual Biotech Company (6) Phase 2a (48 pt) clinical trial in acute coronary syndrome (ACS) completed

More information

IXRS DATA TO INFORMED DECISION MAKING. Linda Chan-Kim October 2015

IXRS DATA TO INFORMED DECISION MAKING. Linda Chan-Kim October 2015 IXRS DATA TO INFORMED DECISION MAKING Linda Chan-Kim October 2015 Table of Contents Genentech Overview EMMA Data Issues What did we do? 2 2 Roche Group An innovation network 3 South San Francisco is home

More information

Risk-Based Monitoring - Prospective from CRO

Risk-Based Monitoring - Prospective from CRO Risk-Based Monitoring - Prospective from CRO New Trends in Clinical Trials Taipei 2016 Tong Guo, PhD Head of Biostatistics, Africa & Asia QuintilesIMS Copyright 2015 Quintiles Disclaimer The views and

More information

Developing a European First-in-Human Study: Three Key Decisions

Developing a European First-in-Human Study: Three Key Decisions Developing a European First-in-Human Study: Three Key Decisions By Nicole Feist, BA Clinical A key step in the translational medicine benchtop to bedside process model is the move from research and preclinical

More information

5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs)

5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs) 5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs) GCP Requirements and Compliance Dr. Katalina Mettke BfArM, Germany Agenda Specialities of Early Development Trials Examples

More information

Corporate Presentation. October 2017

Corporate Presentation. October 2017 Corporate Presentation October 2017 Company Overview OPIS is an international CRO providing: - A wide range of clinical and e-clinical services for Pharmaceutical and Biotechnology Industries, Medical

More information

RBM Risk Based Monitoring GCP Training 12/SEP/2015. Gabor Kiss Synexus Hungary2015

RBM Risk Based Monitoring GCP Training 12/SEP/2015. Gabor Kiss Synexus Hungary2015 RBM Risk Based Monitoring GCP Training 12/SEP/2015 Gabor Kiss Synexus Hungary2015 Agenda Why traditional monitoring must change? The landscape Regulatory Industry IT What can we expect? Transition period

More information

Less is the New More. Alternative models for Source Data Verification (SDV) Anna Wojciuk Clinical Data Manager Biometrics Department KCR

Less is the New More. Alternative models for Source Data Verification (SDV) Anna Wojciuk Clinical Data Manager Biometrics Department KCR Less is the New More Alternative models for Source Data Verification (SDV) Anna Wojciuk Clinical Data Manager Biometrics Department KCR Agenda Guidelines for Industry Regarding Risk Based Monitoring Alternative

More information

FRAMEWORK OF CHARACTERISTICS OF A QUALIFIED SITE TEAM: How Does Yours Measure Up?

FRAMEWORK OF CHARACTERISTICS OF A QUALIFIED SITE TEAM: How Does Yours Measure Up? FRAMEWORK OF CHARACTERISTICS OF A QUALIFIED SITE TEAM: How Does Yours Measure Up? The following framework of characteristics focuses on attributes that are within the control of investigators and their

More information

KCR: Custom-Tailored Functional Service Provider

KCR: Custom-Tailored Functional Service Provider KCR: Custom-Tailored Functional Service Provider KCR is a European Contract Research Organization (CRO) and a strategic solution provider for companies looking for a reliable alternative to global CROs

More information

Vendor-Sponsor Successful Communication. Nathalie Dutil Nov 2012

Vendor-Sponsor Successful Communication. Nathalie Dutil Nov 2012 Vendor-Sponsor Successful Communication Nathalie Dutil Nov 2012 It s all about setting expectations. Lack of communication Miscommunication Presentation overview Strategic Sourcing Oversight Model Trust

More information

THERAPEUTIC AREAS CARDIOVASCULAR RESEARCH

THERAPEUTIC AREAS CARDIOVASCULAR RESEARCH THERAPEUTIC AREAS CARDIOVASCULAR RESEARCH PPD S CARDIOVASCULAR TEAM: OPTIMIZING TRIALS AND IMPROVING OUTCOMES APPLYING EXPERIENCE, INNOVATION AND EFFICIENCY IN THE FIGHT AGAINST CARDIOVASCULAR DISEASE

More information

CRO Oversight - Laissez-faire vs. Micromanagement - oder: Wie viel ist zu viel?

CRO Oversight - Laissez-faire vs. Micromanagement - oder: Wie viel ist zu viel? CRO Oversight - Laissez-faire vs. Micromanagement - oder: Wie viel ist zu viel? X. Interdisziplinaeres Expertengespraech, PPH plus Frankfurt, Mai 8 th, 2015 Jens Opitz Head Corporate Clinical Operations

More information

THE NEW PARADIGMS IN ONCOLOGY CLINICAL TRIALS. Quality Risk Assessment (RBM) & electronic Informed Consent (eic)

THE NEW PARADIGMS IN ONCOLOGY CLINICAL TRIALS. Quality Risk Assessment (RBM) & electronic Informed Consent (eic) THE NEW PARADIGMS IN ONCOLOGY CLINICAL TRIALS Quality Risk Assessment (RBM) & electronic Informed Consent (eic) DEFINITION OF RISK The combination of the probability of occurrence of harm and the severity

More information

Risk-Based Monitoring Update Volume IV

Risk-Based Monitoring Update Volume IV Risk-Based Monitoring Update Volume IV 1. Introduction TransCelerate s Risk-Based Monitoring (RBM) initiative continues to produce tangible outputs during the first half of 2015. The purpose of RBM Update

More information

9 Must-Haves for a Successful Implementation of a Pricing Strategy

9 Must-Haves for a Successful Implementation of a Pricing Strategy 9 Must-Haves for a Successful Implementation of a Pricing Strategy Arjen Brasz Nina Hoette March 2017 www.simon-kucher.com 1 Successful Price Strategy Implementation in B2B No other lever has more impact

More information

Evolving Role of the Data Manager

Evolving Role of the Data Manager 07 November 2016 Evolving Role of the Data Manager 2 Evolution of the Data Manager Role... 2014 2010 Mobility Early 90 s We all simply did it OUR way! No formal measure of data managers' knowledge and

More information

WHY 97% OF ALL PRICE INCREASES FAIL and what your company needs to do different this year

WHY 97% OF ALL PRICE INCREASES FAIL and what your company needs to do different this year WHY 97% OF ALL PRICE INCREASES FAIL and what your company needs to do different this year Image: colourbox.com Philip W. Daus October 2017 www.simon-kucher.com It s that time of the year again. Companies

More information

The Situation of Investigator Initiated Trials in Europe. Dr.N.Gökbuget

The Situation of Investigator Initiated Trials in Europe. Dr.N.Gökbuget The Situation of Investigator Initiated Trials in Europe Dr.N.Gökbuget Investigator Initiated Trials in Europe Difficulties and Possibilities 1. Situation for academic clinical trials after the EU directive

More information

Central Monitoring by Data Management Edit checks, logical checks, automatic review of data, trend analyses

Central Monitoring by Data Management Edit checks, logical checks, automatic review of data, trend analyses Central Monitoring by Data Management Edit checks, logical checks, automatic review of data, trend analyses Michel Arnoult mmb@arnoult.org Stockholm 22 September 2015 Agenda DM Contribution to Data Quality

More information

Improve Trial Efficiency & Quality with CTMS

Improve Trial Efficiency & Quality with CTMS Improve Trial Efficiency & Quality with CTMS Rachel Yang, M.D. Ph.D Director, Product Strategy Oracle Health Sciences Global Business Unit Agenda General trends, and challenges of clinical trial industry

More information

ELEMENTS OF A DATA MONITORING PLAN

ELEMENTS OF A DATA MONITORING PLAN ELEMENTS OF A DATA MONITORING PLAN Definitions Data Monitoring: The regular evaluation of data and documentation collected during a study to ensure both adherence to the approved investigative plan and

More information

Clinical Trial Performance Metrics

Clinical Trial Performance Metrics Clinical Trial Performance Metrics Clinical trial performance metrics? Data points that provide insight into operational and quality of performance. Objectives of Clinical Trial Performance Metrics The

More information

Incorporating Risk- Based Monitoring Strategies: Challenges in Implementation Sherri Hubby, Director, U.S. Quality Assurance

Incorporating Risk- Based Monitoring Strategies: Challenges in Implementation Sherri Hubby, Director, U.S. Quality Assurance Incorporating Risk- Based Monitoring Strategies: Challenges in Implementation Sherri Hubby, Director, U.S. Quality Assurance 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria. Disclaimer The

More information

Recommendations for Strengthening the Investigator Site Community

Recommendations for Strengthening the Investigator Site Community Recommendations for Strengthening the Investigator Site Community October 2017 CTTI MISSION: To develop and drive adoption of practices that will increase the quality and efficiency of clinical trials

More information

QUALITY ASSURANCE. Pharma Quality Agreements: What Are They, and Why They Matter For Your Study ABSTRACT

QUALITY ASSURANCE. Pharma Quality Agreements: What Are They, and Why They Matter For Your Study ABSTRACT WHITE PAPER PRESENTED BY PREMIER RESEARCH Pharma Quality Agreements: What Are They, and Why They Matter For Your Study ABSTRACT Quality Agreements are an effective bridge to a successful future for companies

More information

Global Regulatory Director, Personalized Healthcare

Global Regulatory Director, Personalized Healthcare Date: 11/21/18 Global Regulatory Director, Personalized Healthcare Job ID: 201811-127364 Job Function Research Location United States of America - California South San Francisco Schedule Full time Job

More information

Enabling faster insights to improve clinical trial efficiency and quality

Enabling faster insights to improve clinical trial efficiency and quality Enabling faster insights to improve clinical trial efficiency and quality Clarity, understanding and confidence Every clinical trial has moments when decisive action is needed to set the course for a

More information

Outsourcing in Clinical Trials West Coast: Medical Device Stream Burlingame, CA February 22 nd 2018

Outsourcing in Clinical Trials West Coast: Medical Device Stream Burlingame, CA February 22 nd 2018 Outsourcing in Clinical Trials West Coast: Medical Device Stream Burlingame, CA February 22 nd 2018 Speakers Confirmed: Lian Cunningham, Vice President, Clinical Affairs and Regulatory Affairs, BAROnova

More information

PAREXEL STRATEGIC PARTNERSHIPS. Optimizing relationships for shorter time to market

PAREXEL STRATEGIC PARTNERSHIPS. Optimizing relationships for shorter time to market PAREXEL STRATEGIC PARTNERSHIPS Optimizing relationships for shorter time to market YOUR JOURNEY. OUR MISSION. Delivering a more collaborative and operationally efficient relationship so you can reach your

More information

Welcome. Thank you for joining us. Irina Moissiu, Director Client Relations Laurie Furiness, EVP Operations & Consulting Services

Welcome. Thank you for joining us. Irina Moissiu, Director Client Relations Laurie Furiness, EVP Operations & Consulting Services Welcome Thank you for joining us Irina Moissiu, Director Client Relations Laurie Furiness, EVP Operations & Consulting Services 360 o SERVICE PERFORMANCE MEASUREMENT Sponsor View TM 5 Assessments Available

More information

U.S. FDA CENTER FOR DEVICES AND RADIOLOGICAL HEALTH UPDATE. Jeff Shuren Director Center for Devices and Radiological Health

U.S. FDA CENTER FOR DEVICES AND RADIOLOGICAL HEALTH UPDATE. Jeff Shuren Director Center for Devices and Radiological Health U.S. FDA CENTER FOR DEVICES AND RADIOLOGICAL HEALTH UPDATE Jeff Shuren Director Center for Devices and Radiological Health 21 ST CENTURY CURES ACT IMPLEMENTATION Provision Implementation activities completed

More information

Risk-Based Monitoring in Clinical Trials: A Cross-Functional Approach

Risk-Based Monitoring in Clinical Trials: A Cross-Functional Approach Risk-Based Monitoring in Clinical Trials: A Cross-Functional Approach Sharon Herbert, PhD. - Senior Medical Research Manager Tyson Rogers, MS - Senior Principal Medical Research Biostatistician Clinical

More information

Risk-Based Monitoring Improves Site Performance and Investigator Satisfaction

Risk-Based Monitoring Improves Site Performance and Investigator Satisfaction Insight brief Risk-Based Monitoring Improves Site Performance and Investigator Satisfaction By reading this insight brief, you ll learn how RBM: Leads to earlier insights that improve trial quality Influences

More information

FEBRUARY 2015 D. Lee Spurgin, Jr., PhD

FEBRUARY 2015 D. Lee Spurgin, Jr., PhD FEBRUARY 2015 D. Lee Spurgin, Jr., PhD Resources - Publications Little Advisor ICH-GCP, Investigational Site - English Little Advisor ISO 14155:2011, Sponsor Responsibilities - English Little Advisor ISO

More information

Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd.

Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd. Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd. Copyright 2009 - Pharmaceutical Research & Manufacturers Association 1 Overview Audit ICH-GCP,

More information

Regulatory Documentation and Submissions for C2012 Clinical Trials DCP SOP #1

Regulatory Documentation and Submissions for C2012 Clinical Trials DCP SOP #1 Regulatory Documentation and Submissions for C2012 Clinical Trials DCP SOP #1 Phone: 650.691.4400 Fax: 650.691.4410 Email: regulatory.ccsainc.com COMPLIANCE & STANDARDIZATION Rationale for Revision of

More information

How To Be a Global Player in Early Clinical Development? Dr CHONG Chew Lan Executive Director, Medical Research 07-Nov-2014

How To Be a Global Player in Early Clinical Development? Dr CHONG Chew Lan Executive Director, Medical Research 07-Nov-2014 How To Be a Global Player in Early Clinical Development? Dr CHONG Chew Lan Executive Director, Medical Research 07-Nov-2014 Topics Why early clinical development in Asia-Pacific? Access to patient populations

More information

Framework of Regulation /Guidelines

Framework of Regulation /Guidelines Sponsor Responsibility Site Selection Peculiarities of Early Phase Clinical Trials AGAH Workshop, November 03-04, 2016, Bonn Framework of Regulation /Guidelines New Clinical Trial Regulation 536/2014 EU

More information

Trial Services. The allround trial specialist in cardiology Leading since cardialysis.com

Trial Services. The allround trial specialist in cardiology Leading since cardialysis.com Trial Services The allround trial specialist in cardiology Leading since 1983 cardialysis.com Trial design The key factor in achieving a successful clinical trial is to have a well-prepared, consistent

More information

Course Title ID Duration Basic Premium. Biological Evaluation of Medical Devices: A Risk-Based Approach N mins

Course Title ID Duration Basic Premium. Biological Evaluation of Medical Devices: A Risk-Based Approach N mins Pre-Clinical Basic Level : CMDA Certified Medical Device Associate Biological Evaluation of Medical Devices: A Risk-Based Approach N134 63 mins 186.00 144.00 Introduction to Process Validation N135 75

More information

Medical Director / Senior Medical Director, Atezo GU

Medical Director / Senior Medical Director, Atezo GU Date: 11/09/18 Medical Director / Senior Medical Director, Atezo GU Job ID: 3396269256 Job Function Clinical Operations Location United States of America - California South San Francisco Schedule Full

More information

Your Complete Quality Solution Provider for the Life Science Industry

Your Complete Quality Solution Provider for the Life Science Industry Your Complete Quality Solution Provider for the Life Science Industry PQE at-a-glance Our broad services portfolio, extensive experience, effective project management, and exceptional cost effectiveness,

More information

KNOW-HOW AND ACCURACY IN CLINICAL RESEARCH

KNOW-HOW AND ACCURACY IN CLINICAL RESEARCH KNOW-HOW AND ACCURACY IN CLINICAL RESEARCH Behind every successful and growing organization lies a strong foundation and a great vision. - Vatché Bartekian President A WINNING TEAM Vatché Bartekian President

More information

KNOW-HOW AND ACCURACY IN CLINICAL RESEARCH

KNOW-HOW AND ACCURACY IN CLINICAL RESEARCH KNOW-HOW AND ACCURACY IN CLINICAL RESEARCH Behind every successful and growing organization lies a strong foundation and a great vision. - Vatché Bartekian President A WINNING TEAM Vatché Bartekian President

More information

SAAPI CONFERENCE Nicola Main, B.Pharm CCRA, Clinical Research Manager 04 October 2018

SAAPI CONFERENCE Nicola Main, B.Pharm CCRA, Clinical Research Manager 04 October 2018 SAAPI CONFERENCE Nicola Main, B.Pharm CCRA, Clinical Research Manager 04 October 2018 Phone: 919-361-2286 Fax: 919-361-2290 Email: info@cato.com www.cato.com 1 The Impact of Local and Global Regulations

More information

The Role of the CRO in Effective Risk-Based Monitoring

The Role of the CRO in Effective Risk-Based Monitoring New Whitepaper The Role of the CRO in Effective Risk-Based Monitoring The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging

More information

Veeva 2018 Unified Clinical Operations Survey

Veeva 2018 Unified Clinical Operations Survey PRELIMINARY FINDINGS Veeva 2018 Unified Clinical Operations Survey The Veeva 2018 Unified Clinical Operations Survey examines the life sciences industry s progress toward a unified clinical environment

More information

How can Regulatory Agencies leverage the effectiveness of the Clinical Trials Enterprise

How can Regulatory Agencies leverage the effectiveness of the Clinical Trials Enterprise How can Regulatory Agencies leverage the effectiveness of the Clinical Trials Enterprise 10 th Latin American Conference on Clinical Research, October 2013 Xavier Luria, MD Drug Development and Regulation

More information

The Case for ICH E6(R2) Compliance Assessment

The Case for ICH E6(R2) Compliance Assessment The Case for ICH E6(R2) Compliance Assessment The Clinical landscape has become increasingly challenging due to growing demand from regulators and the public for more and better clinical research results.

More information

Felicia Favorito Clinical Operations Leader TESARO Inc.

Felicia Favorito Clinical Operations Leader TESARO Inc. Felicia Favorito Clinical Operations Leader TESARO Inc. Navigating your way around protocols which intervene with country specific regulations to ensure valuable time isn t lost during the clinical trial

More information

Associate Group Medical Director - MD

Associate Group Medical Director - MD Date: 06/11/18 Associate Group Medical Director - MD Job ID: 201805-106259 Job Function Clinical Development Location United States of America - California South San Francisco Schedule Full time Job type

More information

Reducing the Time to Market with an eclinical System

Reducing the Time to Market with an eclinical System Reducing the Time to Market with an eclinical System Medidata and other marks used herein are trademarks of Medidata Solutions, Inc. All other trademarks are the property of their respective owners. Copyright

More information

GLOBAL Trend and opportunities in drug development

GLOBAL Trend and opportunities in drug development GLOBAL Trend and opportunities in drug development พญ อรณ ต งเผ า Oranee T Daniels MD October 2015 Looking back during last 15 years Drug safety became a focus for both regulators and drug developers.

More information

Biotherapeutic product characterization to support accelerated process development

Biotherapeutic product characterization to support accelerated process development Biotherapeutic product characterization to support accelerated process development Kyle Zingaro, Ph.D. Alexion Pharmaceuticals 2015 Biomanufacturing Technology Summit June 25, 2015 Our Mission: Treating

More information

IMARC Research, Inc. Executive Summary. Independent. Monitoring. Auditing. Research. Consulting WE LL EARN YOUR APPROVAL.

IMARC Research, Inc. Executive Summary. Independent. Monitoring. Auditing. Research. Consulting WE LL EARN YOUR APPROVAL. IMARC Research, Inc. Executive Summary Independent Monitoring Auditing Research Consulting WE LL EARN YOUR APPROVAL. Introduction IMARC Research was founded in 1999 by Harold and Sandy Maddock who both

More information

Hands-on in Latin America Regulations for Clinical Trials

Hands-on in Latin America Regulations for Clinical Trials Hands-on in Latin America Regulations for Clinical Trials Director: Silvia Zieher VP Clinical Development, Latin America Operations INC Research Disclaimer The views and opinions expressed in the following

More information

Identifying Critical Factors Pre-launch

Identifying Critical Factors Pre-launch Identifying Critical Factors Pre-launch Incorporate pricing and market access into product planning Eric M. Bachman, Director Boston office One Canal Park Cambridge, MA 02141, USA Tel. +1 617 231 4592

More information

Client Alert. FDA Offers New Guidance on Acceptance of Foreign Clinical Trials. Introduction. FDA Regulation of Foreign Clinical Trials 6

Client Alert. FDA Offers New Guidance on Acceptance of Foreign Clinical Trials. Introduction. FDA Regulation of Foreign Clinical Trials 6 Number 1325 April 23, 2012 Client Alert Latham & Watkins Corporate Department FDA Offers New Guidance on Acceptance of Foreign Clinical Trials Introduction With this newly released guidance, the FDA seeks

More information

1 The Clinical Research Coordinator (CRC)... 1

1 The Clinical Research Coordinator (CRC)... 1 TABLE OF CONTENTS Dedication... iii Introduction... xi 1 The Clinical Research Coordinator (CRC)... 1 Role and Responsibilities of the CRC...1 Personality and Skills... 3 Where Do CRCs Work?... 3 CRC Responsibilities...

More information

Evaluation of the Prime Partnership between Accelence and Quintiles. James Brook Senior Director, Head Site Management Western Europe, Quintiles

Evaluation of the Prime Partnership between Accelence and Quintiles. James Brook Senior Director, Head Site Management Western Europe, Quintiles Evaluation of the Prime Partnership between Accelence and Quintiles James Brook Senior Director, Head Site Management Western Europe, Quintiles Copyright 2013 Quintiles Revised July 2013 7 BILLION HUMANS

More information

Approaches to Risk-Based Quality Management Quality by Design/Quality Systems

Approaches to Risk-Based Quality Management Quality by Design/Quality Systems Your Partner in Quality Management Approaches to Risk-Based Quality Management Quality by Design/Quality Systems F-Crin Workshop on Risk Management in Clinical Trials Peter Schiemann, PhD Clinical Quality

More information

BIOCLINICA CLINICAL DATA MANAGEMENT

BIOCLINICA CLINICAL DATA MANAGEMENT BIOCLINICA CLINICAL DATA MANAGEMENT Achieve faster speed to market, with Bioclinica s best-in-class Electronic Data Capture (EDC) technology and in-house full-service Data Management (DM) services. $ BIOCLINICA

More information

Natalia Nayanova Director of Clinical Operations and General Manager. Accell Clinical Research 2016

Natalia Nayanova Director of Clinical Operations and General Manager. Accell Clinical Research 2016 Natalia Nayanova Director of Clinical Operations and General Manager Accell Clinical Research 2016 PRESENTATION STRUCTURE Company overview Advantages of the Region FDA & EMA Acceptance Myths vs. Realities

More information

Good Clinical Practice, GCP. Clinical Trials 101 GCIG CCRN QA

Good Clinical Practice, GCP. Clinical Trials 101 GCIG CCRN QA Good Clinical Practice, GCP Clinical Trials 101 GCIG CCRN QA Monica Bacon/Adriana Chavez-Blanco GCIG-CCRN Background: 1949 The Nuremburg Code 1964 Declaration of Helsinki (World Medical Association) 1990

More information

Creating the ideal Approach to gain Balance between effective Oversight and Micromanaging

Creating the ideal Approach to gain Balance between effective Oversight and Micromanaging Creating the ideal Approach to gain Balance between effective Oversight and Micromanaging Karine Pigache-Renard and on behalf of Ulrike M. Grimm 4 th Annual Outsourcing in Clinical Trials Europe Conference,

More information

Good Clinical Practice (GCP) & Clinical Trial Registries

Good Clinical Practice (GCP) & Clinical Trial Registries Good Clinical Practice (GCP) & Clinical Trial Registries The Fifth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practice Forum November 14-17, 2004 Kate Maloney, RN, MS, CPHQ Manager,

More information

ecoa SOLUTIONS Eliminate ecoa complexity so you can move ahead quickly

ecoa SOLUTIONS Eliminate ecoa complexity so you can move ahead quickly ecoa SOLUTIONS Eliminate ecoa complexity so you can move ahead quickly THE PROBLEM WITH COA The quality of collected patient data, study timelines and study costs are influenced by a number of factors,

More information

The 6 th Kitasato-Harvard Symposium Session3:New Challenges Disease Areas. Investigator Initiated Trial (IIT) Future for IIT from the past experience

The 6 th Kitasato-Harvard Symposium Session3:New Challenges Disease Areas. Investigator Initiated Trial (IIT) Future for IIT from the past experience The 6 th Kitasato-Harvard Symposium Session3:New Challenges Disease Areas Investigator Initiated Trial (IIT) Future for IIT from the past experience JMACCT Project Clinical Trial Research Project of JMACCT

More information

Overview of Privacy Requirements and Compliance Issues in International Clinical Trials

Overview of Privacy Requirements and Compliance Issues in International Clinical Trials Overview of Privacy Requirements and Compliance Issues in International Clinical Trials Health Care Compliance Association Research Compliance Conference October 18-20, 2009 Minneapolis, MN 1 Today s Presenters

More information

Adopting Site Quality Management to Optimize Risk-Based Monitoring

Adopting Site Quality Management to Optimize Risk-Based Monitoring WHITE PAPER Adopting Site Quality Management to Optimize Risk-Based Monitoring In today s pressure-packed environment, the quest for improved data quality at a lower cost is of paramount importance to

More information

POSITION DESCRIPTION

POSITION DESCRIPTION POSITION DESCRIPTION Role Description This role will be responsible for the project management and successful delivery of the Procurement Transformation project. The project s objectives are to gain

More information

Annex IV to guidance for the conduct of good clinical practice inspections sponsor and CRO

Annex IV to guidance for the conduct of good clinical practice inspections sponsor and CRO 23 August 2017 EMA/431267/2016 Annex IV to guidance for the conduct of good clinical practice inspections sponsor Adopted by GCP Inspectors Working Group (GCP IWG) 29 November 2017 Keywords GCP inspection,

More information

DANA-FARBER / HARVARD CANCER CENTER STANDARD OPERATING PROCEDURES FOR HUMAN SUBJECT RESEARCH TITLE

DANA-FARBER / HARVARD CANCER CENTER STANDARD OPERATING PROCEDURES FOR HUMAN SUBJECT RESEARCH TITLE SOP #: DATA-101 Page: 1 of 5 1. POLICY STATEMENT: Case Report Forms (CRFs) are designed by the Clinical Trials Research Informatics Office (CTRIO) in collaboration with the Sponsor, Overall PI, designated

More information

GLOBAL TRENDS SURVEY REPORT

GLOBAL TRENDS SURVEY REPORT GLOBAL TRENDS SURVEY REPORT + OVERVIEW Clinical trials have become increasingly global in scope. Some countries require testing of drugs in a country before they can be approved for sale in that country.

More information

MEDICAL DEVICES STUDIES

MEDICAL DEVICES STUDIES AN OVERVIEW OF MEDICAL DEVICES STUDIES Outsourcing Trends & Regulatory Landscape in Europe and Latin America - whitepaper - MARKET & LANDSCAPE At Eurotrials, we work to deliver a best in class solution

More information

MEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155

MEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155 MEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155 EXECUTIVE SUMMARY Medical device regulations around the world generally require manufacturers of most types of medical devices to supply data as part

More information

Regulatory Requirements for Medical Devices in China

Regulatory Requirements for Medical Devices in China Regulatory Requirements for Medical Devices in China Syneos Health TM 2018 Syneos Health. All rights reserved. How to Register a Foreign Medical Device in China Classification Class 1 Class 2 Class 3 Authority

More information

Human Research Protection Program Policy

Human Research Protection Program Policy Page 1 of 5 REVIEW OF INVESTIGATIONAL NEW DRUG (IND)/INVESTIGATIONAL DEVICE EXEMPTION (IDE) RESEARCH IN HUMAN SUBJECTS RESEARCH POLICY It is the policy of the University of Cincinnati that studies involving

More information

Service solutions for peak performance. Flexible service plans, maximum productivity, expert engineers.

Service solutions for peak performance. Flexible service plans, maximum productivity, expert engineers. Service solutions for peak performance Flexible service plans, maximum productivity, expert engineers www.moleculardevices.com Choose the right service plan for your specific laboratory priorities Performance

More information

Inspiring Procurement Excellence PASIA World Conference. November 2016

Inspiring Procurement Excellence PASIA World Conference. November 2016 Inspiring Procurement Excellence PASIA World Conference November 2016 Jess is responsible for developing new business and bringing prospective members within the Asia Pacific region into the CASME community.

More information

Presented by NC TraCS Institute UNC Office of Clinical Trials UNC Network for Research Professionals

Presented by NC TraCS Institute UNC Office of Clinical Trials UNC Network for Research Professionals ORIENTATION FOR NEW CLINICAL RESEARCH COORDINATORS Presented by NC TraCS Institute UNC Office of Clinical Trials UNC Network for Research Professionals Overall Agenda for Orientation Module 1: Introduction

More information

Regulatory issues for academicled multinational trials in Asia: Who takes responsibility?

Regulatory issues for academicled multinational trials in Asia: Who takes responsibility? CVCT Asia Workshop, 15 July 2018 Regulatory issues for academicled multinational trials in Asia: Who takes responsibility? Commentary : Kaori Shinagawa, MD, PhD Senior Scientist for Clinical Medicine Pharmaceuticals

More information

10/06/2016. Sustainable biosimilar policies. Panel discussion - Joint 22 nd Medicines for Europe and 19 th IGBA Annual Conference in Dubrovnik.

10/06/2016. Sustainable biosimilar policies. Panel discussion - Joint 22 nd Medicines for Europe and 19 th IGBA Annual Conference in Dubrovnik. Sustainable biosimilar policies Panel discussion - Joint 22 nd Medicines for Europe and 19 th IGBA Annual Conference in Dubrovnik June 9, 2016 Michael Dilger Matthias Liefner Mark Kastner Nicklas Jacobsen

More information

Calendar. The Clear Solution to Reach the Global Biopharma Audience. INTERNATIONAL

Calendar. The Clear Solution to Reach the Global Biopharma Audience.   INTERNATIONAL The Clear Solution to Reach the Global Biopharma Audience yvdavyd/getty Images & blackred/e+/getty Images 2017 EDITOrial Calendar Editorial Coverage Special Themed Issues January Biopharma Outlook for

More information

Leading with Excellence Successful Models for Planning, Executing & Building Partnerships

Leading with Excellence Successful Models for Planning, Executing & Building Partnerships An ISO 9001:2015 & ISO 29990:2010 Certified Company Leading with Excellence Successful Models for Planning, Executing & Building Partnerships 03-14 Jul 2017 Zurich 25 Sep - 06 Oct 2017 London 10-21 Dec

More information

Latham & Watkins Corporate Department

Latham & Watkins Corporate Department Number 1217 July 20, 2011 Client Alert Latham & Watkins Corporate Department FDA Issues Draft Guidance for In Vitro Companion Diagnostic Devices Although comments on the draft guidance may be submitted

More information

Acurian on. Bolstering Clinical Trial Enrollment with Site Support Services It s All about Relationships

Acurian on. Bolstering Clinical Trial Enrollment with Site Support Services It s All about Relationships Acurian on Bolstering Clinical Trial Enrollment with Site Support Services It s All about Relationships Within the patient enrollment continuum, when a candidate for a clinical trial attends their First

More information

How did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949

How did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949 ICH GCP Overview What is ICH? ICH is a joint initiative involving both the regulators and the industry as equal partners in the scientific and technical discussions of the testing procedures which are

More information

Applying a Knowledge-Based Approach to Pharmaceutical Supply Chain Temperature Control Management

Applying a Knowledge-Based Approach to Pharmaceutical Supply Chain Temperature Control Management May 1-3, 2012 Javits Center New York, NY Applying a Knowledge-Based Approach to Pharmaceutical Supply Chain Control Management Arminda O. Montero Program Manager, Distribution QA Global Pharmaceutical

More information

HELPING DELIVER LIFE-CHANGING THERAPIES HEMATOLOGY ONCOLOGY

HELPING DELIVER LIFE-CHANGING THERAPIES HEMATOLOGY ONCOLOGY HELPING DELIVER LIFE-CHANGING THERAPIES HEMATOLOGY ONCOLOGY PROVIDING COMPREHENSIVE SOLUTIONS IN A COMPLEX ENVIRONMENT PPD IS A PARTNER WITH PROVEN CAPABILITIES THAT SUPPORT AND ADVANCE ONCOLOGY RESEARCH

More information

Conducted Under an IND to Support a

Conducted Under an IND to Support a Using Foreign Clinical Trial Data not Conducted Under an IND to Support a US Application PDA Midwest Chapter Meeting March 15, 2018 2013 2017 Regulatory Compliance Associates Inc. All Rights Reserved.

More information

Tier Assessment/Setting - Quick Guide to Competency Levels

Tier Assessment/Setting - Quick Guide to Competency Levels Tier Assessment/Setting - Quick Guide to Competency Levels RESEARCH OPERATIONS Competency Fundamental Skilled Advanced Interactions with IRB Candidate has used the system to successfully submit documents

More information

GCP INSPECTION FINDINGS Singapore Research Ethics Conference 2018

GCP INSPECTION FINDINGS Singapore Research Ethics Conference 2018 1 GCP INSPECTION FINDINGS Singapore Research Ethics Conference 2018 Sumitra Sachidanandan GCP Inspection Consultant Clinical Trials Branch Health Products Regulation Group Health Sciences Authority Singapore

More information

Review of EU Clinical Trial Directive. 15 May 2012 Mike Beckers Sidley Austin LLP, Brussels

Review of EU Clinical Trial Directive. 15 May 2012 Mike Beckers Sidley Austin LLP, Brussels BEIJING BRUSSELS CHICAGO DALLAS FRANKFURT GENEVA HONG KONG LONDON LOS ANGELES NEW YORK PALO ALTO SAN FRANCISCO SHANGHAI SINGAPORE SYDNEY TOKYO WASHINGTON, D.C. Review of EU Clinical Trial Directive 15

More information

Pharmaceutical Product Development NASDAQ: PPDI. Dan Darazsdi Chief Financial Officer. Credit Suisse Healthcare Conference November 2009

Pharmaceutical Product Development NASDAQ: PPDI. Dan Darazsdi Chief Financial Officer. Credit Suisse Healthcare Conference November 2009 Pharmaceutical Product Development NASDAQ: PPDI Dan Darazsdi Chief Financial Officer Credit Suisse Healthcare Conference 2009 12 November 2009 Safe Harbor Except for historical information, all of the

More information

Contact:: (609) Details please visit our website:

Contact:: (609) Details please visit our website: SunGen Pharma aims to create a healthier future for patients while increasing shareholder value through the development and introduction of quality, affordable generic products by experienced, passionate

More information

BEST PRACTICES FOR RANDOMIZATION AND TRIAL SUPPLY MANAGEMENT (RTSM)

BEST PRACTICES FOR RANDOMIZATION AND TRIAL SUPPLY MANAGEMENT (RTSM) WHITE PAPER BEST PRACTICES FOR RANDOMIZATION AND TRIAL SUPPLY MANAGEMENT (RTSM) Guidelines for Sponsor IRT Strategy Study Start-Up, Maintenance and Close-Out Bringing crucial medicines to those who need

More information